Friday, May 1, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The New Era of Patient Empowerment

Summary
In this episode, the host discusses the evolving dynamics between patients and physicians in the post-pandemic healthcare landscape. The conversation highlights the shift from a paternalistic approach to a more collaborative relationship, where patients actively engage in their healthcare decisions. The rise of healthcare consumerism, particularly in relation to GLP-1 medications, is explored, emphasizing the importance of trust and effective communication in modern medical practice. The host advocates for empowering patients through information and adapting to their needs in this new era of medicine.
Takeaways

  • Patients are increasingly researching their own healthcare options.
  • The pandemic has shifted the patient-physician dynamic towards collaboration.
  • Healthcare consumerism is reshaping how patients view their health.
  • Physicians must engage with patients’ research and concerns.
  • Trust is a critical component in the patient-physician relationship.
  • Effective communication is essential for patient empowerment.
  • Patients want to be in control of their healthcare decisions.
  • The definition of research is evolving in the digital age.
  • Physicians should guide patients in their information-seeking process.
  • Understanding patient behavior is key to providing quality care.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!